Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;97(1147):312-320.
doi: 10.1136/postgradmedj-2020-138577. Epub 2020 Sep 25.

COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment

Anant Parasher  1
Affiliations
Review

COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment

Anant Parasher. Postgrad Med J. 2021 May.

Abstract

Background: The severe acute respiratory syndrome (SARS) coronavirus-2 is a novel coronavirus belonging to the family Coronaviridae and is now known to be responsible for the outbreak of a series of recent acute atypical respiratory infections originating in Wuhan, China. The disease caused by this virus, termed coronavirus disease 19 or simply COVID-19, has rapidly spread throughout the world at an alarming pace and has been declared a pandemic by the WHO on March 11, 2020. In this review, an update on the pathophysiology, clinical presentation and the most recent management strategies for COVID-19 has been described.

Materials and methods: A search was conducted for literature and various articles/case reports from 1997 to 2020 in PUBMED/MEDLINE for the keywords coronavirus, SARS, Middle East respiratory syndrome and mRNA virus.

Results and conclusions: COVID-19 has now spread globally with increasing morbidity and mortality among all populations. In the absence of a proper and effective antibody test, the diagnosis is presently based on a reverse-transcription PCR of nasopharyngeal and oropharyngeal swab samples. The clinical spectrum of the disease presents in the form of a mild, moderate or severe illness. Most patients are either asymptomatic carriers who despite being without symptoms have the potential to be infectious to others coming in close contact, or have a mild influenza-like illness which cannot be differentiated from a simple upper respiratory tract infection. Moderate and severe cases require hospitalisation as well as intensive therapy which includes non-invasive as well as invasive ventilation, along with antipyretics, antivirals, antibiotics and steroids. Complicated cases may require treatment by immunomodulatory drugs and plasma exchange therapy. The search for an effective vaccine for COVID-19 is presently in full swing, with pharmaceutical corporations having started human trials in many countries.

Keywords: Virology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
The severe acute respiratory syndrome coronavirus-2 life cycle.
Figure 2
Figure 2
Pathophysiology of COVID-19. CXCL-10, C-X-C motif chemokine ligand 10; IFN, interferon; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TNF-α, tumour necrosis factor-α; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
Figure 3
Figure 3
Treatment protocol for patients with COVID-19. RR, respiratory rate; SpO2, oxygen saturation; HCQS, hydroxychloroquine; ECG, electrocardiogram; HFNO, high flow nasal oxygen; NIV, non-invasive ventilation; I/V, intravenous; LMWH, low molecular weight heparin; CBC, complete blood count; LDH, lactate dehydrogenase; CRP, c- reactive protein; ICU, intensive care unit; ARDS, acute respiratory distress syndrome.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review [published online ahead of print, 2020 Apr 20]. Clin Immunol. 2020; 215:108427.10.1016/j.clim.2020.108427 - DOI - PMC - PubMed
    1. Ksiazek TG, Erdman D, Goldsmith CS, et al. Group A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.10.1056/NEJMoa030781 - DOI - PubMed
    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.10.1056/NEJMoa2001316 - DOI - PMC - PubMed
    1. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020.10.1038/s41423-020-0402-2 - DOI - PMC - PubMed
    1. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis 2020;20:793–802.10.1016/S1473-3099(20)30230-9 - DOI - PMC - PubMed

MeSH terms